Skip to main content
. 2018 Jul 20;9(56):30869–30882. doi: 10.18632/oncotarget.25766

Figure 1. Molecular heterogeneity detected in silico in 331 HCC lesions with a known mutational profile.

Figure 1

(A) In silico analysis showing the number of mutations (≥ 4) detected in 331 patients (validation cohorts). (B) Percentage of total hits involved in the indicated signaling pathways.